Developing groundbreaking therapeutics for patients with life-threatening cancers
Advancing targeted oncolytic immunotherapies to address patient need
Bringing hope to patients who need improved treatments for solid tumors
Jennerex is focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors. Our lead product, Pexa-Vec (JX-594), is a proprietary, oncolytic immunotherapy designed to attack cancer through three diverse mechanisms of action. See how it works.